1
|
Firouzi M, Haghighijoo Z, Eskandari M, Mohabbati M, Miri R, Jamei MH, Poustforoosh A, Nazari S, Firuzi O, Khoshneviszadeh M, Edraki N. Synthesis and cytotoxic activity evaluation of novel imidazopyridine carbohydrazide derivatives. BMC Chem 2024; 18:6. [PMID: 38184605 PMCID: PMC10770970 DOI: 10.1186/s13065-023-01073-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Accepted: 10/30/2023] [Indexed: 01/08/2024] Open
Abstract
Two series of novel imidazo[1,2-a]pyridine-2-carbohydrazide derivatives have been designed, synthesized, and evaluated for cytotoxic activity. Target compounds were designed in two series: aryl hydrazone derivatives that were devoid of triazole moiety (7a-e) and aryl triazole bearing group (11a-e). In vitro cytotoxicity screening was carried out using MTT assay against three human cancer cells including breast cancer (MCF-7), colon cancer (HT-29), and leukemia (K562) cell lines as well as a non-cancer cell line (Vero). Compound 7d bearing 4-bromophenyl pendant from aryl hydrazone series exhibited the highest cytotoxic potential with IC50 values of 22.6 µM and 13.4 µM against MCF-7 and HT-29 cells, respectively, while it was not toxic towards non-cancer cells up to the concentration of 100 µM. Cell cycle analysis revealed that 7d increased the number of MCF-7 cells in the G0/G1 phase and also induced apoptosis in these cells as revealed by Hoechst 33,258 staining. The molecular mechanism contributing to the anti-proliferative effect of the most potent compound was investigated in silico using Super Pred software and introduced PDGFRA as a plausible target for 7d. Molecular docking and molecular dynamic studies demonstrated Lys627 and Asp836 as key residues interacting with the active compound. Overall, 7d could serve as a suitable candidate for further modifications as a lead anticancer structure.
Collapse
Affiliation(s)
- Maryam Firouzi
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
- Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Zahra Haghighijoo
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Masoomeh Eskandari
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Maryam Mohabbati
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Ramin Miri
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mohammad Hasan Jamei
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
- Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Alireza Poustforoosh
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Somayeh Nazari
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Omidreza Firuzi
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mehdi Khoshneviszadeh
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
| | - Najmeh Edraki
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
| |
Collapse
|
2
|
Sıcak Y, Aktar BSK, Yılmaz GT, Öztürk FA, Öztürk M, Tok TT, Emre EE. Design, Synthesis, Pharmacological Activities, Structure-Activity Relationship, and In Silico Studies of Novel 5-Substituted-2-(morpholinoimino)-thiazolidin-4-ones. ACS OMEGA 2023; 8:38641-38657. [PMID: 37867693 PMCID: PMC10586451 DOI: 10.1021/acsomega.3c05928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Accepted: 09/20/2023] [Indexed: 10/24/2023]
Abstract
This study is aimed to synthesize morpholine- and thiazolidine-based novel 5-(substituted)benzylidene)-2-(morpholinoimino)-3-phenylthiazolidin-4-ones (3-26) and characterized by molecular spectroscopy. The synthesized compounds were subjected to antioxidant activity with anticholinesterase, tyrosinase, and urease inhibition activities and evaluated the structure-activity relationship (SAR) of enzyme inhibition activities. Compound 11 was found to be the most active antioxidant. In anticholinesterase inhibition, compound 12 (IC50: 17.41 ± 0.22 μM) was the most active against AChE, while compounds 3-26 ( except 3, 8, and 17) showed notable activity against BChE. Compounds 17 (IC50: 3.22 ± 0.70 mM), 15 (IC50: 5.19 ± 0.03 mM), 24 (IC50: 7.21 ± 0.27 mM), 23 (IC50: 8.05 ± 0.11 mM), 14 (IC50: 8.10 ± 0.22 mM), 25 (IC50: 8.40 ± 0.64 mM), 26 (IC50: 8.76 ± 0.90 mM), and 22 (IC50: 9.13 ± 0.55 mM) produced higher tyrosinase inhibition activity. In urease inhibition activity, compounds 20 (IC50: 16.79 ± 0.19 μM), 19 (IC50: 18.25 ± 0.50 μM), 18 (IC50: 20.24 ± 0.77 μM), 26 (IC50: 21.51 ± 0.44 μM), 25 (IC50: 21.70 ± 0.06 μM), and 24 (IC50: 22.49 ± 0.11 μM) demonstrated excellent activities. Besides, the molecular docking study was applied to better understand the inhibitory mechanism between (1-26) compounds and enzymes at the molecular level. According to the results of this study, the synthesized compounds exhibited a better binding affinity toward these enzymes compared to the positive control. Further, molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) binding free energy and molecular dynamics (MD) simulation analyses were performed for AChE with compound 26, which showed high inhibitory activity in silico and in vitro studies. In conclusion, novel morpholine and thiazolidine-based derivative compounds may be pharmacologically effective agents for AChE, BChE, tyrosinase, and urease enzymes.
Collapse
Affiliation(s)
- Yusuf Sıcak
- Department
of Medicinal and Aromatic Plants, Köyceğiz Vocational
School, Muğla Sıtkı Koçman
University, Köyceğiz, Muğla 48800, Turkey
| | - Bedriye Seda Kurşun Aktar
- Department
of Hair Care and Beauty Services, Yeşilyurt Vocational School, Malatya Turgut Özal University, Malatya 44210, Turkey
| | - Gizem Tatar Yılmaz
- Department
of Biostatistics and Medical Informatics, Faculty of Medicine, Karadeniz Technical University, Trabzon 61080, Turkey
| | - Fatma Aydoğmuş Öztürk
- Department
of Medicinal and Aromatic Plants, Köyceğiz Vocational
School, Muğla Sıtkı Koçman
University, Köyceğiz, Muğla 48800, Turkey
| | - Mehmet Öztürk
- Department
of Chemistry, Faculty of Sciences, Muğla
Sıtkı Koçman University, Muğla 48121, Turkey
| | - Tuğba Taşkın Tok
- Department
of Chemistry, Faculty of Arts and Sciences, Gaziantep University, Gaziantep 27310, Turkey
| | - Emine Elçin
Oruç Emre
- Department
of Chemistry, Faculty of Arts and Sciences, Gaziantep University, Gaziantep 27310, Turkey
| |
Collapse
|
3
|
Begunov RS, Sokolov AA. Biological Activity of Condensed Pyridine Derivatives with a Bridgehead Nitrogen Atom. Pharm Chem J 2023. [DOI: 10.1007/s11094-023-02827-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2023]
|
4
|
Divar M, Tadayyon S, Khoshneviszadeh M, Pirhadi S, Attarroshan M, Mobaraki K, Damghani T, Mirfazli S, Edraki N. Benzyl‐Triazole Derivatives of Hydrazinecarbothiamide Derivatives as Potent Tyrosinase Inhibitors: Synthesis, Biological Evaluation, Structure‐Activity Relationship and Docking Study. ChemistrySelect 2023. [DOI: 10.1002/slct.202203382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Affiliation(s)
- Masoumeh Divar
- Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences 7134853734 Shiraz Iran
| | - Somayeh Tadayyon
- Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences 7134853734 Shiraz Iran
- Department of Medicinal Chemistry School of Pharmacy Shiraz University of Medical Sciences 7146864685 Shiraz Iran
| | - Mehdi Khoshneviszadeh
- Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences 7134853734 Shiraz Iran
- Department of Medicinal Chemistry School of Pharmacy Shiraz University of Medical Sciences 7146864685 Shiraz Iran
| | - Somayeh Pirhadi
- Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences 7134853734 Shiraz Iran
| | - Mahshid Attarroshan
- Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences 7134853734 Shiraz Iran
| | - Kourosh Mobaraki
- Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences 7134853734 Shiraz Iran
- Department of Medicinal Chemistry School of Pharmacy Shiraz University of Medical Sciences 7146864685 Shiraz Iran
| | - Tahereh Damghani
- Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences 7134853734 Shiraz Iran
| | - Sara Mirfazli
- Department of Medicinal Chemistry School of Pharmacy Iran University of Medical Sciences 1475886671 Tehran Iran
| | - Najmeh Edraki
- Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences 7134853734 Shiraz Iran
| |
Collapse
|
5
|
Padmaja P, Reddy PN, Reddy BS, Tiwari AK, Ugale VG, Komati A, Sridhar B. Design, synthesis, in vitro α-glucosidase inhibitory, antioxidant activity and molecular docking studies of novel pyridine linked imidazo[1,2-a]pyridine derivatives. J Mol Struct 2022. [DOI: 10.1016/j.molstruc.2022.134238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
6
|
Newly Designed Quinazolinone Derivatives as Novel Tyrosinase Inhibitor: Synthesis, Inhibitory Activity, and Mechanism. Molecules 2022; 27:molecules27175558. [PMID: 36080324 PMCID: PMC9457556 DOI: 10.3390/molecules27175558] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Revised: 08/20/2022] [Accepted: 08/24/2022] [Indexed: 11/18/2022] Open
Abstract
We synthesized a series of quinazolinone derivates as tyrosinase inhibitors and evaluated their inhibition constants. We synthesized 2-(2,6-dimethylhepta-1,5-dien-1-yl)quinazolin-4(3H)-one (Q1) from the natural citral. The concentration, which led to 50% activity loss of Q1, was 103 ± 2 μM (IC50 = 103 ± 2 μM). Furthermore, we considered Q1 to be a mixed-type and reversible tyrosinase inhibitor, and determined the KI and KIS inhibition constants to be 117.07 μM and 423.63 μM, respectively. Our fluorescence experiment revealed that Q1 could interact with the substrates of tyrosine and L-DOPA in addition to tyrosinase. Molecular docking studies showed that the binding of Q1 to tyrosinase was driven by hydrogen bonding and hydrophobicity. Briefly, the current study confirmed a new tyrosinase inhibitor, which is expected to be developed into a novel pigmentation drug.
Collapse
|
7
|
El Kalai F, Baydere C, Dege N, Abudunia A, Benchat N, Karrouchi K. Crystal structure and Hirshfeld surface analysis of 2-oxo-2-phenylethyl 3-nitroso-2-phenylimidazo[1,2-a]pyridine-8-carboxylate. Acta Crystallogr E Crystallogr Commun 2022; 78:322-325. [PMID: 35371553 PMCID: PMC8900504 DOI: 10.1107/s2056989022001517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 02/08/2022] [Indexed: 11/18/2022]
Abstract
In the crystal, molecules are linked by C—H⋯O hydrogen bonds, generating (5) and (28) ring motifs. In addition, weak C—H⋯π and π-stacking interactions are observed. The title compound, C22H15N3O4, is built up from a central imidazo[1,2-a]pyridine ring system connected to a nitroso group, a phenyl ring and a 2-oxo-2-phenylethyl acetate group. The imidazo[1,2-a] pyridine ring system is almost planar (r.m.s. deviation = 0.017 Å) and forms dihedral angles of 22.74 (5) and 45.37 (5)°, respectively, with the phenyl ring and the 2-oxo-2-phenylethyl acetate group. In the crystal, the molecules are linked into chains parallel to the b axis by C—H⋯O hydrogen bonds, generating R21 (5) and R44 (28) graph-set motifs. The chains are further linked into a three-dimensional network by C—H⋯π and π-stacking interactions. The intermolecular interactions were investigated using Hirshfeld surface analysis and two-dimensional fingerprint plots, revealing that the most important contributions for the crystal packing are from H⋯H (36.2%), H⋯C/C⋯H (20.5%), H⋯O/O⋯H (20.0%), C⋯O/O⋯C (6.5%), C⋯N/N⋯C (6.2%), H⋯N/N⋯H (4.5%) and C⋯C (4.3%) interactions.
Collapse
|
8
|
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met. Sci Rep 2021; 11:3644. [PMID: 33574356 PMCID: PMC7878917 DOI: 10.1038/s41598-021-83069-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2020] [Accepted: 01/28/2021] [Indexed: 01/01/2023] Open
Abstract
Aberrant activation of c-Met signalling plays a prominent role in cancer development and progression. A series of 12 imidazo [1,2-α] pyridine derivatives bearing 1,2,3-triazole moiety were designed, synthesized and evaluated for c-Met inhibitory potential and anticancer effect. The inhibitory activity of all synthesized compounds against c-Met kinase was evaluated by a homogeneous time-resolved fluorescence (HTRF) assay at the concentration range of 5-25 µM. Derivatives 6d, 6e and 6f bearing methyl, tertiary butyl and dichloro-phenyl moieties on the triazole ring, respectively, were the compounds with the highest potential. They significantly inhibited c-Met by 55.3, 53.0 and 51.3%, respectively, at the concentration of 25 µM. Synthetic compounds showed antiproliferative effects against lung (EBC-1) and pancreatic cancer cells (AsPc-1, Suit-2 and Mia-PaCa-2) expressing different levels of c-Met, with IC50 values as low as 3.0 µM measured by sulforhodamine B assay. Active derivatives significantly blocked c-Met phosphorylation, inhibited cell growth in three-dimensional spheroid cultures and also induced apoptosis as revealed by Annexin V/propidium iodide flow cytometric assay in AsPc-1 cells. They also inhibited PDGFRA and FLT3 at 25 µM among a panel of 16 kinases. Molecular docking and dynamics simulation studies corroborated the experimental findings and revealed possible binding modes of the select derivatives with target receptor tyrosine kinases. The results of this study show that some imidazopyridine derivatives bearing 1,2,3-triazole moiety could be promising molecularly targeted anticancer agents against lung and pancreatic cancers.
Collapse
|